| 1.26 0.04 (3.28%) | 07-02 09:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.72  |
1-year : | 2.21 |
| Resists | First : | 1.47 |
Second : | 1.89 |
| Pivot price | 1.34 |
|||
| Supports | First : | 0.8 | Second : | 0.66 |
| MAs | MA(5) : | 1.3 |
MA(20) : | 1.35 |
| MA(100) : | 2.13 |
MA(250) : | 3.9 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 17.7 |
D(3) : | 21.8 |
| RSI | RSI(14): 42.4 |
|||
| 52-week | High : | 9.48 | Low : | 0.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ FNCH ] has closed above bottom band by 20.8%. Bollinger Bands are 63.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.22 - 1.23 | 1.23 - 1.23 |
| Low: | 1.2 - 1.21 | 1.21 - 1.22 |
| Close: | 1.21 - 1.22 | 1.22 - 1.23 |
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Sat, 24 Feb 2024
Finch Therapeutics Faces Nasdaq Delisting and Patent Litigation - TipRanks.com - TipRanks
Fri, 09 Jun 2023
Finch Announces Reverse Stock Split of Common Stock - Yahoo Finance
Wed, 19 Apr 2023
4 Penny Stocks To Buy According To Analysts, Targets Up To 1,560% - Penny Stocks
Tue, 18 Apr 2023
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and ... - GlobeNewswire
Mon, 03 Apr 2023
Finch Therapeutics: Why This Finch Could Fly? Asymmetric Risk/Reward Opportunity (FNCH) - Seeking Alpha
Tue, 24 Jan 2023
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 53.4 (%) |
| Held by Institutions | 11.3 (%) |
| Shares Short | 19 (K) |
| Shares Short P.Month | 11 (K) |
| EPS | -9.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.85 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22 % |
| Return on Equity (ttm) | -62.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -13.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.13 |
| PEG Ratio | 0 |
| Price to Book value | 0.1 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|